Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alnylam Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Issues 2022 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY REGN
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.